Editorial - Direct-acting antivirals therapy in HCV patients with HCC: lights and shadow.
暂无分享,去创建一个
B. Rinaldi | L. Rinaldi | V. Rosato | R. Galiero | E. Vetrano | M. Fasano
[1] C‐J. Chen,et al. Effects of direct-acting antiviral therapy for patients with advanced hepatocellular carcinoma and concomitant hepatitis C-A population-based cohort study. , 2021, European review for medical and pharmacological sciences.
[2] A. Tamori,et al. Direct‐acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment , 2021, Journal of viral hepatitis.
[3] A. Masumoto,et al. Serum α‐fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct‐acting antiviral treatment , 2021, Journal of viral hepatitis.
[4] G. Cabibbo,et al. Direct-acting antiviral agents and risk of Hepatocellular carcinoma: critical appraisal of the evidence. , 2021, Annals of hepatology.
[5] H. Nomura,et al. Long‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antivirals , 2021, Journal of gastroenterology and hepatology.
[6] P. Hayes,et al. Uptake of interferon‐free DAA therapy among HCV‐infected decompensated cirrhosis patients and evidence for decreased mortality , 2021, Journal of viral hepatitis.
[7] F. Bazzoli,et al. Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis , 2021, Journal of clinical medicine.
[8] G. Finley,et al. Influence of Social Determinants of Health on Timeliness to Treatment for Metastatic HCC and the Impact of Affordable Care Act , 2021 .
[9] G. Cabibbo,et al. Antiviral therapy in the palliative setting of HCC (BCLC B and C). , 2021, Journal of hepatology.
[10] M. Krahn,et al. Impact of direct‐acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta‐analysis , 2021, Journal of viral hepatitis.
[11] E. Shin,et al. Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection , 2021, Journal of clinical medicine.
[12] M. Giordano,et al. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct‐acting antiviral therapy: A prospective study , 2020, Diabetes, obesity & metabolism.
[13] M. Giordano,et al. Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics , 2020, Cancers.
[14] Anish H. Patel,et al. Decreased risk of hepatocellular carcinoma recurrence with direct-acting antivirals compared with no treatment for hepatitis C: a meta-analysis , 2020, Annals of gastroenterology.
[15] M. Giordano,et al. Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. , 2020, Atherosclerosis.
[16] A. Gawish,et al. Changing Patterns of Hepatocellular Carcinoma after Treatment with Direct Antiviral Agents , 2020, Gastrointestinal Tumors.
[17] E. Orsi,et al. Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[18] B. Rinaldi,et al. Features of microvessel density (MVD) and angiogenesis inhibitors in therapeutic approach of hepatocellular carcinoma (HCC). , 2019, European review for medical and pharmacological sciences.
[19] F. Ciardiello,et al. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study , 2019, Journal of Translational Medicine.
[20] M. Guarino,et al. Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience , 2019, Digestive Diseases and Sciences.
[21] M. Omata,et al. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review , 2019, International journal of molecular sciences.
[22] G. Corazza,et al. Mortality rate and risk factors for gastrointestinal bleeding in elderly patients. , 2019, European journal of internal medicine.
[23] G. Cabibbo,et al. Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients , 2019, Digestive and Liver Disease.
[24] A. Tamori,et al. Cure With Interferon‐Free Direct‐Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma From Both East and West , 2020, Hepatology.
[25] R. D. de Knegt,et al. Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals. , 2017, Gastroenterology.
[26] X. Forns,et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. , 2017, Journal of hepatology.
[27] M. Imamura,et al. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib , 2017, Oncology.
[28] L. Rinaldi,et al. Serial Liver Stiffness Measurements and Monitoring of Liver-Transplanted Patients in a Real-Life Clinical Practice , 2016, Hepatitis monthly.
[29] L. Rinaldi,et al. HEPATOCELLULAR CARCINOMA IN HCV CIRRHOSIS AFTER VIRAL CLEARANCE WITH DIRECT ACTING ANTIVIRAL THERAPY : PRELIMINARY EVIDENCE AND POSSIBLE MEANINGS , 2016 .
[30] F. Drago,et al. Elevated serum levels of Chromogranin A in hepatocellular carcinoma , 2012, BMC Surgery.
[31] U. Tirelli,et al. Anal cancer: Focus on HIV-positive patients in the HAART-era. , 2011, Current HIV research.
[32] M. Masetti,et al. Don't deny liver transplantation to HIV patients with hepatocellular carcinoma in the highly active antiretroviral therapy era. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.